Gilead Shines Some Light On Its Inflammation Ambitions

Part Of Ongoing Diversification Strategy

 
• By Mandy Jackson
  
Gilead announced a new deal and reworked an old deal in inflammation already this year (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Conferences